Recompensation in Cirrhosis: Rewriting the Natural History-Recompensation

Video Transcription

Video Summary

The webinar discussed “recompensation” in cirrhosis, the process by which some patients with previously decompensated cirrhosis improve after removal or control of the underlying cause. Speakers reviewed how compensated cirrhosis can progress to decompensation through portal hypertension, then sometimes improve again with effective treatment such as alcohol abstinence, HCV cure, or HBV suppression. They emphasized that recompensation is associated with markedly lower liver-related and overall mortality.<br /><br />Three clinical cases were used to guide discussion. For alcohol-related cirrhosis, the panel generally supported considering tapering diuretics and encephalopathy medications only after prolonged stability, strong confidence in sustained abstinence, and shared decision-making. They noted that rifaximin is often the last drug stopped, especially if encephalopathy was severe or portosystemic shunts persist. For MASH cirrhosis, they said true recompensation is possible but less common and harder to achieve; GLP-1 drugs and bariatric surgery are often limited by decompensation, sarcopenia, and safety concerns, so nutrition and diabetes control remain key. For HCV cirrhosis after SVR, they highlighted that portal hypertension and varices may persist, so non-selective beta-blockers are often continued unless risk can be confidently ruled out.<br /><br />Overall, the panel stressed individualized care, cautious medication withdrawal, monitoring, and the importance of transplant-center follow-up.

Keywords

recompensation

cirrhosis

portal hypertension

decompensated cirrhosis

alcohol abstinence

HCV cure

HBV suppression

MASH cirrhosis

transplant center follow-up